Vaccine CDMO Market Revenue to Attain USD 36.28 Bn by 2033

01 Sep 2025

Share :

Table of Content

1. Vaccine CDMO Market Revenue and Trends 2025 to 2033 2. What are the Key Factors Influencing the Market Growth? 3. Segment Insights: 4. Regional Insights 5. Vaccine CDMO Market Coverage

Vaccine CDMO Market Revenue and Trends 2025 to 2033

The vaccine CDMO market size was calculated at USD 5.09 million in 2025 and is expected to reach around USD 10.23 million by 2033, expanding at a CAGR of 9.1% from 2025 to 2033. The growth of the market is attributed to the increasing global demand for vaccines, the rapid adoption of advanced platforms like mRNA, and the rising trend of outsourcing vaccine manufacturing.

What are the Key Factors Influencing the Market Growth?

The vaccine CDMO market is experiencing significant growth, fueled by escalating global demand for vaccines due to emerging infectious diseases, expanded immunization efforts, and rising public health concerns. This market’s growth is further propelled by pharmaceutical companies' increasing reliance on CDMOs for cost reduction, accelerated time-to-market, and access to specialized expertise in complex biologics manufacturing. However, the market faces several restraints, including high investment costs, regulatory complexities, capacity limitations, supply chain vulnerabilities, and intense competition. Despite these challenges, the rising development of mRNA and next-generation vaccines, strategic alliances, global market expansion, technological advancements, and personalized therapies, solidifying the role of CDMOs as essential collaborators in vaccine innovation and supply. Technological advancements in vaccine technologies, such as mRNA and viral vectors, coupled with governmental support through investments and initiatives, are creating immense opportunities in the market.

Segment Insights:

• By modality, the mRNA vaccines segment led the market in 2024, driven by sustained demand following the success of COVID-19 mRNA vaccines, which demonstrated proven efficacy and rapid development. The rising demand for effective therapies to curb the spread of infectious diseases further supports segmental growth.
• By expression system/platform, the mammalian cell culture segment dominated the vaccine CDMO market in 2024 due to its essential role in producing complex biologics with greater safety and efficacy. Its ability to support high-yield production of glycosylated proteins made it the preferred platform for many advanced vaccines.
• By manufacturing scale, the commercial scale segment contributed the largest market share in 2024 driven by the increasing number of vaccines reaching late-stage approval and entering global distribution. The increased global demand for novel vaccines, the need for large-volume production, and partnerships between the pharmaceutical companies and CDMOs also bolstered segmental growth.
• By dosage form/presentation, the liquid formulation segment dominated the market in 2024, primarily due to the ease of administration, lower production costs, favorable product stability, and widespread adoption in large-scale immunization programs. Their compatibility with a wide range of vaccine types, including mRNA, viral vector, and protein subunit vaccines, further contributed to their dominance.

Regional Insights

North America sustained dominance in the vaccine CDMO market, holding the largest share in 2024. This is mainly due to its well-developed biopharmaceutical infrastructure, robust R&D capabilities, and substantial investments from leading pharmaceutical and biotechnology companies. The region's dominance also stems from established CDMOs that can rapidly implement new vaccine platforms, including mRNA and viral vectors, facilitating quick development and large-scale manufacturing. Government initiatives, favorable regulations, and significant healthcare expenditures further support market growth, solidifying North America's leading position in the global vaccine CDMO landscape.

Asia Pacific is expected to experience rapid growth in the market, driven by escalating vaccine demand, rising healthcare expenditures, and increased healthcare expenditure. Countries such as India, China, and South Korea are expanding their vaccine manufacturing capabilities, offering cost-effective outsourcing solutions to global pharmaceutical companies. The swift adoption of new vaccine technologies and growing focus on pandemic preparedness, supported by government policies, further contribute to regional market growth. 

Vaccine CDMO Market Coverage

Recent Development

• In November 2024, FUJIFILM Diosynth Biotechnologies announced the completion of the first phase of its Hillerød site expansion, adding new production capacity. This marks a key step in its strategy to build a global ecosystem for advancing the manufacturing and delivery of life-saving biologics and vaccines. ( Source: https://www.fujifilm.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6679

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344